The U.S. Food and Drug Administration (FDA) has accepted Sentynl Therapeutics Inc.’s New Drug Application (NDA) for CUTX-101 ...

“Today marks a significant milestone in Halia’s journey,” said Dr. David J. Bearss, President & CEO of Halia Therapeutics.

Nitroxoline has not been approved by the FDA, and its use is therefore considered investigational. FLA patients will receive ...

Gaelic Laboratories, a European CMO based in Ireland, has established a subsidiary in the UAE, enabling access to the Middle ...

Innovent Biologics Inc., a biopharmaceutical company that develops, manufactures and commercializes medicines, has entered a ...

The KOASTAL-1 study enrolled 383 adult patients with MDD. Navacaprant was shown to be safe and generally well-tolerated with ...

Chime Biologics, a global CDMO, and Mabgeek, a clinical-stage innovative antibody drug development biotech, have successfully ...

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, has appointed Lori ...

Veeda Group has unveiled a new logo and brand identity— Veeda Lifesciences —reflecting the brand’s evolution from a ...

Averaging up to 20% of weight loss, adults taking Zepbound had 25 fewer breathing interruptions each hour as they slept.

Sangamo plans to explore all options to commercialize the Hemophilia A asset.

Becomes the first subcutaneously administered PD-1 inhibitor.